Free · No account required · Powered by AI across the world's largest grants + funders database
Currently focused on US federal, state, and foundation grants.
Reducing the Burden of Preeclampsia is sponsored by Gates Foundation Trust. Seeking innovative solutions for the early detection, prevention, and treatment of preeclampsia. The challenge focuses on identifying biomarkers to predict risk, developing point-of-care tests, and leveraging digital health or nutritional interventions to reduce maternal and neonatal morbidity and mortality, particularly in resource-limited settings.
Geographic focus: Global (priority for low- and middle-income countries)
Focus areas: Maternal Health, Diagnostics, Global Health
Official opportunity description and requirements excerpt:
Reducing the Burden of Preeclampsia Reducing the Burden of Preeclampsia Before applying, applicants should familiarize themselves with the supporting documents for this Grand Challenge , including the terms and conditions of the Gates Foundation , the Rules and Guidelines , Application Instructions , and Frequently Asked Questions . If you are planning to apply to this RFP, we will be hosting a dedicated webinar on February 27, from 7:30 to 8:30 AM Pacific Time . This session will provide a comprehensive overview of the RFP details and an opportunity to have your questions answered. To participate in the webinar, please register and submit your questions in advance . If you cannot attend live, the webinar will be recorded and available on this challenge page after the session. Preeclampsia is a leading cause worldwide of maternal morbidity and mortality, premature birth, stillbirth, and neonatal death. Preeclampsia is a placental disease caused by two different pathologies during pregnancy. Early-onset disease, caused by reduced uteroplacental blood supply, is a major driver of fetal mortality. Late-onset disease, caused by increased fetoplacental demands, is a major driver of maternal morbidity and mortality. These two pathologies converge on elevated levels of the protein sFlt1 and concomitant decreases in PlGF. This mechanistic understanding is being translated into new strategies to reduce the burden of preeclampsia. Therapeutic candidates are being developed that target sFlt1 activity, and levels of this protein can be used in screening for preeclampsia risk. Effective screening and low-dose aspirin therapy early in pregnancy has been shown to prevent early-onset preeclampsia and to ameliorate the disease's consequences for the fetus. Despite the growing understanding of preeclampsia biology, questions remain about heterogeneity of the disease across patients and the degree to which there are distinct subtypes and etiologies. New approaches are also needed to more quickly and comprehensively reduce the burden of preeclampsia, especially those suitable for the health care infrastructure in the countries with the highest burden. We seek proposals for innovative solutions for the early detection, prevention, and treatment of preeclampsia, particularly in low- and middle-income countries where maternal mortality rates are high. To support this focus, we are looking for collaborations, including those with research institutions, health care providers, and global health organizations, that enable cross-sector insights and ensure that solutions are adaptable and practical. The objectives of the challenge are: Early prediction and detection of preeclampsia . We seek novel biomarkers as well as novel approaches to measurement of sFlt1 and PlGF, diagnostic tests, and point-of-care technologies to predict early in pregnancy
Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Reducing the Burden of Preeclampsia Reducing the Burden of Preeclampsia Before applying, applicants should familiarize themselves with the supporting documents for this Grand Challenge , including the terms and conditions of the Gates Foundation , the Rules and Guidelines , Application Instructions , and Frequently Asked Questions .
If you are planning to apply to this RFP, we will be hosting a dedicated webinar on February 27, from 7:30 to 8:30 AM Pacific Time . This session will provide a comprehensive overview of the RFP details and an opportunity to have your questions answered. To participate in the webinar, please register and submit your questions in advance .
If you cannot attend live, the webinar will be recorded and available on this challenge page after the session. Preeclampsia is a leading cause worldwide of maternal morbidity and mortality, premature birth, stillbirth, and neonatal death. Preeclampsia is a placental disease caused by two different pathologies during pregnancy.
Early-onset disease, caused by reduced uteroplacental blood supply, is a major driver of fetal mortality. Late-onset disease, caused by increased fetoplacental demands, is a major driver of maternal morbidity and mortality. These two pathologies converge on elevated levels of the protein sFlt1 and concomitant decreases in PlGF.
This mechanistic understanding is being translated into new strategies to reduce the burden of preeclampsia. Therapeutic candidates are being developed that target sFlt1 activity, and levels of this protein can be used in screening for preeclampsia risk. Effective screening and low-dose aspirin therapy early in pregnancy has been shown to prevent early-onset preeclampsia and to ameliorate the disease's consequences for the fetus.
Despite the growing understanding of preeclampsia biology, questions remain about heterogeneity of the disease across patients and the degree to which there are distinct subtypes and etiologies. New approaches are also needed to more quickly and comprehensively reduce the burden of preeclampsia, especially those suitable for the health care infrastructure in the countries with the highest burden.
We seek proposals for innovative solutions for the early detection, prevention, and treatment of preeclampsia, particularly in low- and middle-income countries where maternal mortality rates are high.
Based on current listing details, eligibility includes: Nonprofit organizations, for-profit companies, international organizations, government agencies, and academic institutions. Applications from women-led organizations and institutions in low- and middle-income countries are highly encouraged. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Up to $500,000 Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is March 25, 2026. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
View foundation profile, grantmaking history, financials, and key people.
View Foundation ProfileApplication snapshot: target deadline March 25, 2026; published funding information Up to $500,000; eligibility guidance Nonprofit organizations, for-profit companies, international organizations, government agencies, and academic institutions. Applications from women-led organizations and institutions in low- and middle-income countries are highly encouraged.
Use the official notice and source links for final requirements, attachment checklists, allowable costs, and submission instructions before applying.
To support this focus, we are looking for collaborations, including those with research institutions, health care providers, and global health organizations, that enable cross-sector insights and ensure that solutions are adaptable and practical. The objectives of the challenge are: Early prediction and detection of preeclampsia .
We seek novel biomarkers as well as novel approaches to measurement of sFlt1 and PlGF, diagnostic tests, and point-of-care technologies to predict early in pregnancy the risk of preeclampsia and to diagnose it before symptoms become severe. Understanding the pathophysiology of preeclampsia and its heterogeneity .
We seek to understand the biological mechanisms driving the disease and its subtypes so that new interventions can be effectively tailored to the underlying etiology. Preventive and therapeutic interventions . We seek new approaches to known targets or new targets to reduce the incidence and severity of preeclampsia, mitigate disease progression, and prevent the cardiovascular and metabolic complications that often follow it.
We will consider proposals for awards of up to $500,000 USD for each project, with a grant term of up to 2 years. Application budgets should be commensurate with the scope of work proposed. Indirect costs will be considered, and should be included in the budget for the up to $500,000 USD award (subject to the Gates Foundation's indirect cost policy ).
This initiative is open to nonprofit organizations, for-profit companies, international organizations, government agencies, and academic institutions. We particularly encourage applications involving projects led by women or from women-led organizations and applications from institutions based in low- and middle-income countries.
We are looking for proposals that: Identify biomarkers that easily, reliably, and affordably predict preeclampsia risk early in pregnancy Identify biochemical, genetic, epigenetic, or metabolomic signatures that can be translated into point-of-care tests Leverage innovations in mobile health, wearable sensors, or simple clinical algorithms to identify women at risk before symptoms become severe Identify the underlying biological mechanisms driving preeclampsia and its subtypes, including the roles of the placenta, endothelial function, immune response, and gut microbiota Identify preventive interventions synergistic with or additive to low-dose aspirin, such as nutritional, pharmacological, or lifestyle-related approaches to reduce the incidence or severity of preeclampsia Identify new drug candidates, therapeutics, or repurposed medications that safely mitigate preeclampsia progression without harming the fetus We will not fund proposals that: Focus on implementation science, health systems integration, or social determinants (although these are all important elements, they are not in the scope of this request for proposals) Do not have the potential to become affordable and scalable in resource-limited settings Represent basic research without clear relevance to the objectives of this challenge Lack a clearly articulated and testable hypothesis Present unacceptable safety risks or detract from or interfere with beneficial practices Approaches that leverage previously failed biomarker exploration Initiative Grand Challenges Challenge Topic Preeclampsia Burden Date Open Feb 11, 2025, 10:00 am PST Date Closed Mar 25, 2025, 11:30 am PDT An Affordable, All-in-One Point-of-Care Device for Early Preeclampsia Detection Advancing Early Preeclampsia Detection: A Cohort Study on Urinary Biomarkers Activin A and Inhibin A Point-of-Care Lateral Flow Assay for Early Preeclampsia Risk Stratification in Remote Settings Transforming Preeclampsia Risk Screening and Prevention in Sub-Saharan African Countries Point-of-Care Rapid Test for Early Diagnosis of Preeclampsia via sFlt1 See All Direct and Related Awards Reducing the Burden of Preeclampsia - RFP Reducing the Burden of Preeclampsia RFP - Chinese Reducing the Burden of Preeclampsia RFP - French Reducing the Burden of Preeclampsia RFP - Korean Reducing the Burden of Preeclampsia RFP - Portuguese Reducing the Burden of Preeclampsia RFP - Spanish Reducing the Burden of Preeclampsia - Rules and Guidelines Reducing the Burden of Preeclampsia - Application Instructions Reducing the Burden of Preeclampsia - Budget Template and Narrative Reducing the Burden of Preeclampsia - Webinar Slides Reducing the Burden of Preeclampsia - Frequently Asked Questions (FAQs) Reducing the Burden of Preeclampsia - Webinar Video Great ideas come from everywhere.
View the Grand Challenges partnership network The Gates Foundation is part of the Grand Challenges partnership network. Visit www. grandchallenges.
org to view the map of awarded grants across this network and grant opportunities from partners. We are a nonprofit fighting poverty, disease, and inequity around the world. Be Aware of Fraudulent Activity
© 2026 Granted AI